This trial will compare the effectiveness of osimertinib alone to osimertinib with SRS for brain metastases in patients with newly diagnosed EGFR positive lung cancer.
1 Primary · 9 Secondary · Reporting Duration: 2 years
Active Control
Experimental Treatment
76 Total Participants · 2 Treatment Groups
Primary Treatment: Osimertinib · No Placebo Group · Phase 2
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: